Otto Zhou

Alb albumin ALL acute lymphoblastic leukemia ARA-C cytarabine BCP-ALL B-cell precursor acute lymphoblastic leukemia CI confidence interval CNS central nervous system consolidation-1 first consolidation phase CSF cerebrospinal fluid CTCAE Common Terminology Criteria for Adverse Events CVC central vein catheter HR high risk ICU Intensive Care Unit IQR interquartile range IR intermediate risk ITT intrathecal therapy MRD minimal residual disease N/A not applicable NCI National Cancer Institute...

1 INTRODUCTION Acute lymphoblastic leukemia (ALL), constituting approximately 25% of pediatric cancers,1 has five-year survival rates of over 90% when treated with the contemporary protocols.2, 3 Thus, the number of survivors is increasing. Treatment is intensive, commonly associated with severe adverse effects, and may require long periods of absence from school.